PharmGen Science Inc (004720.KS)
PharmGen Science, Inc. engages in the research and development, production, and sale of pharmaceutical products in South Korea. It provides prescription drugs, OTC drugs, diagnostic test kits, health and general foods, and cosmetics, as well as shampoo, conditioner, and hair oil products under the neomcell brand name. The company was formerly known as Wooridul Pharmaceutical Limited and changed its name to PharmGen Science, Inc. PharmGen Science, Inc. was founded in 1957 and is headquartered in Hwaseong-si, South Korea.
Company Info
Highlights
₩77.53B
₩171.66B
₩108.49B
₩3,640.00 - ₩6,430.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
PharmGen Science Inc (004720.KS) returned 4.52% year-to-date (YTD) and -19.19% over the past 12 months. Over the past 10 years, 004720.KS returned -6.10% annually, underperforming the S&P 500 benchmark at 10.85%.
004720.KS
4.52%
6.61%
-7.57%
-19.19%
-19.84%
-7.93%
-6.10%
^GSPC (Benchmark)
0.51%
5.49%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 004720.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.38% | 1.62% | -9.36% | 1.01% | 6.61% | 4.52% | |||||||
| 2024 | -5.65% | -1.71% | -1.91% | -5.67% | -0.56% | -0.95% | 1.34% | -3.39% | -4.09% | -3.25% | -2.84% | -11.57% | -34.03% |
| 2023 | 1.95% | -7.64% | -3.18% | 5.09% | -4.84% | -3.94% | 1.03% | 3.55% | 8.82% | -18.62% | 11.81% | 2.31% | -7.19% |
| 2022 | -8.29% | -5.50% | 4.29% | -15.17% | 3.11% | -17.95% | 11.45% | -0.13% | -21.24% | 26.30% | -6.90% | -4.84% | -36.38% |
| 2021 | -17.35% | -4.71% | 0.45% | 76.17% | -32.38% | 9.86% | -0.00% | -16.58% | 42.42% | -15.11% | -2.12% | -9.09% | -7.08% |
| 2020 | -0.00% | -11.93% | 9.80% | 8.44% | -3.29% | -0.77% | 45.55% | 97.75% | -18.97% | -14.72% | -2.75% | -8.87% | 77.39% |
| 2019 | 15.54% | -4.33% | -3.67% | -2.28% | -11.95% | 6.05% | -14.88% | -1.96% | -0.00% | 0.33% | 0.83% | 4.94% | -13.92% |
| 2018 | -3.93% | 17.73% | -3.09% | -5.18% | -13.45% | -13.50% | -8.87% | 7.76% | 1.14% | -27.23% | 12.89% | 1.79% | -35.37% |
| 2017 | 2.61% | -9.89% | 71.16% | -40.29% | -39.57% | -13.91% | -5.31% | -5.73% | -13.34% | 37.96% | -10.39% | 41.18% | -33.62% |
| 2016 | 1.19% | 4.72% | 14.51% | 0.62% | 69.32% | 2.89% | 14.74% | -2.75% | 11.95% | 6.18% | -5.56% | -3.36% | 157.46% |
| 2015 | 12.37% | 5.26% | -2.27% | 4.96% | 20.38% | -20.00% | -5.52% | 1.46% | 8.32% | 1.03% | -9.94% | 8.77% | 20.07% |
| 2014 | 2.95% | -2.15% | -2.93% | 2.76% | -0.49% | -1.47% | 7.98% | -1.85% | -24.47% | -5.30% | 19.08% | 54.14% | 37.10% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 004720.KS is 21, meaning it’s performing worse than 79% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for PharmGen Science Inc (004720.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the PharmGen Science Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the PharmGen Science Inc was 91.85%, occurring on Nov 7, 2014. The portfolio has not yet recovered.
The current PharmGen Science Inc drawdown is 87.43%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -91.85% | Sep 14, 2012 | 528 | Nov 7, 2014 | — | — | — |
| -90.86% | Mar 15, 2006 | 648 | Oct 29, 2008 | 949 | Sep 13, 2012 | 1597 |
| -87.34% | Jul 15, 1997 | 231 | Jun 29, 1998 | 426 | Mar 16, 2000 | 657 |
| -82.27% | Mar 27, 2000 | 720 | Mar 11, 2003 | 659 | Nov 7, 2005 | 1379 |
| -45.08% | Oct 16, 1996 | 56 | Jan 8, 1997 | 89 | May 19, 1997 | 145 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of PharmGen Science Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of PharmGen Science Inc, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how PharmGen Science Inc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 004720.KS compared to other companies in the Drug Manufacturers - General industry. 004720.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 004720.KS relative to other companies in the Drug Manufacturers - General industry. Currently, 004720.KS has a P/S ratio of 0.5. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 004720.KS in comparison with other companies in the Drug Manufacturers - General industry. Currently, 004720.KS has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |